B of A Securities Maintains Underperform on Intercept Pharma, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Geoff Meacham maintains an Underperform rating on Intercept Pharma (NASDAQ:ICPT) and lowers the price target from $17 to $14.
May 23, 2023 | 11:24 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
B of A Securities maintains an Underperform rating on Intercept Pharma and lowers the price target from $17 to $14.
The lowered price target by B of A Securities indicates a bearish outlook on Intercept Pharma's stock. The Underperform rating suggests that the stock is expected to underperform the market in the short term. This news is highly relevant and important for investors in ICPT, and the confidence in the analysis is high due to the credibility of B of A Securities.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100